Patent ID: 11945872
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 5:
6. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody has one or more properties selected from the group consisting of:
(a) is a fully human monoclonal antibody; (b) binds to human ACVR1 extracellular domain fused to an Fc (e.g., SEQ ID NO: 339) at 25° C. with a dissociation constant (KD) of less than 60 nM, less than 12 nM, less than less than 2 nM, less than 1 nM, or less than 0.5 nM as measured in a surface plasmon resonance assay; (c) binds to human ACVR1 extracellular domain fused to mFc (SEQ ID NO: 339) at 37° C. with a dissociation constant (KD) of less than 150 nM, less than nM, less than less than 5 nM, less than 1.5 nM, or less than 1 nM as measured in a surface plasmon resonance assay; (d) binds to human ACVR1 extracellular domain fused to myc-myc-hexahistag (e.g., SEQ ID NO: 338) at 25° C. with a KD of less than 300 nM, less than 150 nM, less than 25 nM, less than 10 nM, less than 5 nM, less than 3 nM or less than 2 nM as measured in a surface plasmon resonance assay; (e) binds to human ACVR1 extracellular domain fused to myc-myc-hexahistag (e.g., SEQ ID NO: 338) at 37° C. with a KD of less than 500 nM, less than 50 nM, less than 25 nM, less than 10 nM, as measured in a surface plasmon resonance assay; (f) does not bind mouse ACVR1 or binds to mouse ACVR1 extracellular domain fused to myc-myc-hexahistag (e.g., SEQ ID NO: 340) at 25° C. with a KD of greater than 500 nM, as measured in a surface plasmon resonance assay; (g) does not bind mouse ACVR1 or binds to mouse ACVR1 extracellular domain fused to myc-myc-hexahistag (e.g., SEQ ID NO: 340) at 37° C. with a KD of greater than 500 nM, as measured in a surface plasmon resonance assay; (k) binds to cells expressing human ACVR1 protein or human ACVR1 (R206H) protein; (l) inhibits activation of cells expressing human ACVR1(R206H) by human Activin A with a IC50 of less than 25 nM, as measured in a cell-based bioassay; (m) inhibits activation of cells expressing human ACVR1(R206H) by human BMP7 with a IC50 of less than 20 nM, less than 5 nM, less than 3 nM, or less than 1 nM, or less than as measured in a cell-based bioassay; (m) significantly decreases serum hepcidin when administered to mice expressing human ACVR1 in place of mouse allele; (n) significantly increases serum iron levels when administered to mice expressing human ACVR1 in place of mouse allele; and/or (o) inhibits wild-type ACVR1 signaling when administered to mice expressing human ACVR1 in place of mouse allele; and (p) comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 42/48 and 58/62.